Tumor microenvironment in colorectal cancer patients
Sponsored content organized gnosticsNovember 1, 2023Review by Maria Osipova Genetic and cellular screens are essential for understanding the genotype and phenotype of specific cells, providing important insights into disease treatment and prognosis. Immunohistochemistry, in particular, when combined with advances in tissue cytometry and gene sequencing, enables detailed analysis of the tumor microenvironment, uncovering the mechanisms […]
Tip sheet: Health disparities in colorectal cancer, caregiver stories, new ways to study old tumor samples, and Lung Cancer Awareness Month
SEATTLE — November 2, 2023 — Below is a summary of recent research findings and other news from Fred Hutchinson Cancer Center. November is Lung Cancer Awareness Month. If you are looking for resources, please see our media tip sheet and contact us at hplatisha@fredhutch.org. To set up an interview. Do you want to cover […]
Oncolytic therapy meets efficacy criteria in third-line colorectal cancer cohort of GOBLET study
The results met the efficacy criteria for expanded registration and supported Perolep’s mechanism of action. san diego and Calgary, Alabama, October 23, 2023 /PRNewswire/ — Oncolytic Biotechnology® Inc. (NASDAQ: Oncy(Oncolytics) (TSX: ONC), an oncology-focused clinical-stage immunotherapy company, today announced that microsatellite Discuss metastatic colorectal cancer (CRC) regardless of its instability status. madrid, spain. Oncolytics_Biotech_Grey “The […]
Psychological concerns after breast cancer diagnosis and treatment in young adults
Advances in early detection and treatment of breast cancer, including new clinical trials, have significantly improved the prognosis for women with breast cancer in recent years.1 However, as survival rates for breast cancer patients improve, new challenges are emerging. Being diagnosed with and undergoing treatment for breast cancer as a young adult (ages 20-39) can […]
Sotorasib and panitumumab named new standard of care for metastatic colorectal cancer
The combination of sotorasib and panitumumab outperformed researchers’ treatment of choice in a phase 3 trial in chemotherapy-resistant patients. classG12C– Mutant metastatic colorectal cancer (CRC). Researchers tested the combination with two different doses of sotorasib and found that both doses improved progression-free survival (PFS). However, outcomes were better with higher doses of sotorasib. “The combination […]
Lumakras Plus Vectibix improves PFS in colorectal cancer
Patients with colorectal cancer had improved progression-free survival with the combination of Lumaclas and Vectibix. Treatment with Lumaclas (sotorasib) in combination with Vectibix (panitumumab) at multiple dose levels significantly increases patient progression-free survival (PFS) and disease progression from random assignment in clinical trials compared to standard of care (SOC). (time to progression or death).Have chemotherapy-resistant […]
A combination that beats standard treatments for metastatic colorectal cancer
October 23, 2023 2 minute read Add topics to email alerts Receive an email when a new article is posted Enter your email address to receive emails when new articles are posted. . ” data-action=”subscribe”> Subscribe Your request could not be processed. Please try again later. If you continue to experience […]
Individualized survival planning for colon cancer patients receiving adjuvant chemotherapy
Healthcare providers caring for colon cancer survivors need personalized survival plans for patients that monitor for cancer recurrence while also managing other long-term effects, according to a review published in It is necessary to formulate a clinical colorectal cancer.1 Although colon cancer remains one of the most commonly diagnosed cancers in the United States, the […]
Targeted combination therapy triumphs in KRAS-positive metastatic colorectal cancer
MADRID — The combination of a KRAS G12C inhibitor and an EGFR inhibitor significantly improved progression-free survival (PFS) compared to standard of care in patients with chemotherapy-resistant metastatic colorectal cancer (mCRC). was shown in the randomized phase III CodeBreaK 300 trial. With a median follow-up of 7.8 months, median PFS was 5.6 months for patients […]
Maximal tumor debulking with systemic therapy does not affect QoL in mCRC
Colorectal cancer, medical illustration 3D illustration: © Anatomy Insider – Stock.adobe.com Results from ORCHESTRA’s prespecified exploratory analysis show that even the addition of maximal tumor debulking to standard systemic therapy is associated with lower risk of cancer in patients with metastatic colorectal cancer (mCRC) compared to systemic therapy alone. trial (NCT01792934) that had no significant […]